Back to results
TerminatedPhase 1Phase 2

Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

NCT05041101

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

M D Anderson Cancer Center

Houston, Texas, United States

View on ClinicalTrials.gov
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer — TrialFind